Due to the use of nanotechnologies the developers significantly improved physical and chemical properties of active substances of the drug. In addition, a new combinatorial treatment solution has been found. For the first time two active substances (nifedipine and lidocaine) were combined to provide both therapeutic and analgesic effects. The investigational drug is a non-greasy gel which makes it easy to use and ensures long storage life.
This study aims to evaluate the safety, tolerability and pharmacokinetics of the drug provided as a single dose therapy in healthy volunteers.
This is a full-service clinical project in which OCT will provide full project management services from trial monitoring to drug registration. OCT has already successfully completed a number of pre-clinical studies for this project. OCT has extensive experience in phase I clinical trials in a variety of therapeutic areas.